ArticleActa pharmaceutica Sinica. B2023
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Discovery of novel tumor-targeting peptide-oncolytic peptide based conjugates (PPCs): A new paradigm for targeted oncolytic-immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression.iScience · 2026Article
- Aquatic-derived antimicrobial peptides and their strategically modified analogues as prospective anticancer therapeutics: a comprehensive systematic review of enhancement methodologies and mechanistic insights.Frontiers in chemistry · 2026Review
- Negative Immune Checkpoint Inhibitors.Pharmaceutics · 2025Review
- Recent Advances in Augmenting the Therapeutic Efficacy of Peptide-Drug Conjugates.Journal of medicinal chemistry · 2025Review
- Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.Molecular cancer · 2025Review
- Twist1 Regulates the Immune Checkpoint VISTA and Promotes the Proliferation, Migration and Progression of Pancreatic Cancer Cells.Journal of cellular and molecular medicine · 2025Article
- Peptide-based drugs in immunotherapy: current advances and future prospects.Medical oncology (Northwood, London, England) · 2025Review
- Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2025Article
- A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy.Biomarker research · 2024Review
- Review
- Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing.Acta pharmaceutica Sinica. B · 2024Review
- Peptide drugs: a new direction in cancer immunotherapy.Cancer biology & medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing new therapeutic agents for cancer immunotherapy is highly demanding due to the low response ratio of PD-1/PD-L1 blockade in cancer patients. Here, we discovered that the novel immune checkpoint VISTA is highly expressed on a variety of tumor-infiltrating immune cells, especially myeloid derived suppressor cells (MDSCs) and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.